PT - JOURNAL ARTICLE ED - , TI - Potassium hydroxide 5% for the treatment of molluscum contagiosum AID - 10.1136/dtb.2014.10.0285 DP - 2014 Oct 01 TA - Drug and Therapeutics Bulletin PG - 118--120 VI - 52 IP - 10 4099 - http://dtb.bmj.com/content/52/10/118.short 4100 - http://dtb.bmj.com/content/52/10/118.full SO - Drug Ther Bull2014 Oct 01; 52 AB - Molluscum contagiosum is a common reason for consultation in primary care. The condition is normally benign and self-limiting1 and the standard advice is to wait for the lesions to resolve spontaneously.2 Recently, potassium hydroxide 5% (MolluDab—Alliance Pharmaceuticals Limited) has been marketed in the UK for the treatment of the condition.3 It is sold as a medical device rather than a licensed medicinal product. Here we consider the evidence for potassium hydroxide 5% in the management of molluscum contagiosum.